Live Conference Call and Webcast at 5:00 p.m. Eastern Time
THE WOODLANDS, Texas, Oct. 30 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today reported financial results for the three and nine months ended September 30, 2007.
"We continued to make progress in our 10to10 initiative in the third quarter, completing the Phase 1b clinical trial of LX1031, our drug candidate for the treatment of irritable bowel syndrome," said Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer. "The studies demonstrated that LX1031 was well-tolerated at all dose levels and we look forward to advancing it into Phase 2 clinical trials in 2008."
Highlights of the Third Quarter
-- Lexicon scientists presented data revealing the target of a new class
of internally-developed compounds that includes LX1031 and other
compounds under evaluation by the company as potential treatments for
irritable bowel syndrome (IBS) and other gastrointestinal disorders.
The compounds inhibit tryptophan hydroxylase 1 (TPH1), the key enzyme
responsible for producing serotonin in the gastrointestinal tract. In
preclinical studies with these molecules, serotonin levels could be
reduced in the intestine without affecting levels of the
neurotransmitter in the brain, where it mediates mood and other
-- Lexicon received stockholder approval for and completed a financing
transaction with Invus, L.P., under which Invus made an initial common
stock investment of $205 milli
|SOURCE Lexicon Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved